22q11 Deletion Syndrome
0
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
NateraAUSTIN, TX
1 programSNP-based Microdeletion and Aneuploidy RegisTry (SMART)N/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Innovation PharmaceuticalsAware Program
NateraSNP-based Microdeletion and Aneuploidy RegisTry (SMART)
Clinical Trials (2)
Total enrollment: 21,070 patients across 2 trials
Mindfulness Program for Adolescents With 22q11DS
Start: Dec 2023Est. completion: Aug 2024110 patients
N/ACompleted
SNP-based Microdeletion and Aneuploidy RegisTry (SMART)
Start: Apr 2015Est. completion: Jun 202020,960 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.